Consensus Collegium Pharmaceutical, Inc. Boerse Muenchen

Stocks

354 US19459J1043

Pharmaceuticals

Real-time Boerse Muenchen 08:44:00 2026-10-06 EDT			5-day change	1st Jan Change
19.50 ^EUR	0.00%		-2.01%	-53.57%

09-23	Collegium's Durable Cash Flow From Pain Portfolio Poised to Support Further Business Development, Oppenheimer Says	MT
09-23	Oppenheimer Initiates Collegium Pharmaceutical at Outperform With $50 Price Target	MT

0db2e719f4457c7af3b130a364ad0.XBxdV3j6U-GiwHfRb2t-p1PrcnSTePF5i_gvIrOwVmw.FFsWABTIZZLgkSK4HQIQ5iukRjX8EpUJx5Z6VoTKOAE9ehI0PZMAufuMJg~2996e403bd9f0bb1702c10bbb0d3ab24

Analysts' recommendations: Collegium Pharmaceutical, Inc.

09-23	Collegium's Durable Cash Flow From Pain Portfolio Poised to Support Further Business Development, Oppenheimer Says	MT
09-23	Oppenheimer Initiates Collegium Pharmaceutical at Outperform With $50 Price Target	MT
09-09	Leerink Partners Initiates Coverage on Collegium Pharmaceutical With Outperform Rating, $45 Price Target	MT
09-09	Truist Cuts Price Target on Collegium Pharmaceutical to $49 From $58, Keeps Buy Rating	MT
02-10	Truist Adjusts Price Target on Collegium Pharmaceutical to $58 From $55, Maintains Buy Rating	MT
01-07	Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $55 From $48, Maintains Buy Rating	MT
12-09	Barclays Initiates Collegium Pharmaceutical at Overweight With $58 Price Target	MT
11-07	Truist Raises Price Target on Collegium Pharmaceutical to $48 From $45, Keeps Buy Rating	MT
25-08-08	Truist Raises Price Target on Collegium Pharmaceutical to $45 From $42, Keeps Buy Rating	MT
25-08-07	Collegium Pharma Q2 revenue beats analyst expectations	RE
25-01-10	Needham Upgrades Collegium Pharmaceutical to Buy From Hold, Price Target is $46	MT
24-08-09	Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $42 From $40, Maintains Buy Rating	MT
24-07-30	HC Wainwright Upgrades Collegium Pharmaceutical to Buy From Neutral, Price Target is $47	MT
24-06-07	Jefferies Upgrades Collegium Pharmaceutical to Buy From Hold, Adjusts Price Target to $44 From $41	MT
24-05-10	Needham Downgrades Collegium Pharmaceutical to Hold From Buy	MT
24-05-10	Piper Downgrades Collegium Pharmaceutical to Neutral From Overweight, Price Target at $39	MT
24-02-26	Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating	MT
24-02-26	Truist Adjusts Price Target on Collegium Pharmaceutical to $40 From $37, Maintains Buy Rating	MT
24-01-04	Truist Adjusts Collegium Pharmaceutical's Price Target to $37 From $31, Keeps Buy Rating	MT
24-01-04	Jefferies Downgrades Collegium Pharmaceutical to Hold From Buy, Raises Price Target to $37 From $30	MT
23-08-25	Needham Adjusts Price Target on Collegium Pharmaceutical to $36 From $35, Maintains Buy Rating	MT
23-05-02	Jefferies Assumes Collegium Pharmaceutical at Buy With $30 Price Target	MT
23-01-05	Needham Adjusts Price Target on Collegium Pharmaceutical to $35 From $34, Maintains Buy Rating	MT
22-11-04	Needham Adjusts Price Target on Collegium Pharmaceutical to $34 From $36, Maintains Buy Rating	MT
22-08-08	HC Wainwright Downgrades Collegium Pharmaceutical to Neutral From Buy	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+16.25%
	JOHNSON & JOHNSON					+10.5%
	ABBVIE INC.					+4.93%
	MERCK & CO., INC.					+12.05%
	ROCHE HOLDING AG					+7.67%
	NOVARTIS AG					+8.24%
	ASTRAZENECA PLC					+34.74%
	AMGEN INC.					-2.99%
	GILEAD SCIENCES, INC.					+9.7%
	Average					+11.23%
	Weighted average by Cap.					+11.85%